Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BST-104 is a standardized botanical extract derived from **Lonicera Flos**, the dried flower buds of *Lonicera japonica* (Japanese honeysuckle). Developed by the South Korean biotechnology company **Braintropia**, it is primarily investigated for the treatment of mild to moderate **functional dyspepsia** (FD). The extract is rich in bioactive polyphenols and flavonoids, such as chlorogenic acid and luteolin, which are thought to provide gastroprotective and anti-inflammatory benefits. BST-104 aims to alleviate common dyspeptic symptoms, including epigastric pain, bloating, and postprandial fullness, by protecting the gastric mucosa from oxidative stress and modulating inflammatory pathways. It has been evaluated in randomized, double-blind, placebo-controlled clinical trials in South Korea to establish its efficacy and safety profile as a natural therapeutic option for gastric disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BST-104.